Small Pharma Inc (TSX-V:DMT) chief medical and scientific officer Dr Carol Routledge tells Proactive it has completed phase one and started phase two of the clinical trial of its psychedelic-assisted therapy for major depressive disorder (MDD). The company’s DMT-based lead candidate, SPL026, is being tested in combination with psychotherapy. Dr Routledge says the intravenous drug was found to be very well tolerated in individuals with no previous experience of psychedelics.